Consensus statement on the use of alemtuzumab in daily clinical practice in Spain

Introduction: Alemtuzumab is a highly effective drug approved by the European Medicines Agency as a disease-modifying drug for the treatment of relapsing-remitting multiple sclerosis. Objective: A consensus document was drafted on the management of alemtuzumab in routine clinical practice in Spain....

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	J.E. Meca-Lallana, M. Fernández-Prada, E. García Vázquez, S. Moreno Guillén, S. Otero Romero, M. Rus Hidalgo, L.M. Villar Guimerans, S. Eichau Madueño, Ó. Fernández Fernández, G. Izquierdo Ayuso, J.C. Álvarez Cermeño, C. Arnal García, R. Arroyo González, L. Brieva Ruiz, C. Calles Hernández, A. García Merino, M. González Plata, M.Á. Hernández Pérez, E. Moral Torres, J. Olascoaga Urtaza, P. Oliva-Nacarino, C. Oreja-Guevara, R. Ortiz Castillo, A. Oterino, J.M. Prieto González, L. Ramió-Torrentá, A. Rodríguez-Antigüedad, A. Saiz, M. Tintoré, X. Montalbán Gairin
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Elsevier España 2022-10-01
Цуврал:	Neurología (English Edition)
Нөхцлүүд:	Alemtuzumab Eficacia Esclerosis múltiple España Práctica clínica habitual Seguridad
Онлайн хандалт:	http://www.sciencedirect.com/science/article/pii/S2173580820300158
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!